32 results about "Proton pump" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

The invention relates to the technical field of biological engineering, and discloses a method for enhancing the urea circulation function of a 3D biological printing liver organ, which comprises the following steps: a cell preparation step: through a genetic engineering technology, enabling mitochondria of liver cells to express a light-driven proton pump, and enabling intracellular expression of a fluorescent probe for reporting ammonia concentration; an organ construction step: mixing the cells with hydrogel to prepare bio-ink, and constructing a three-dimensional liver organ by using a 3D biological printing technology; a system integration step: placing the liver organ in an integrated photoelectric regulation and control system capable of monitoring a fluorescence signal in real time and applying illumination; and a closed-loop enhancement step: the system monitors the ammonia concentration in real time, and when the ammonia concentration exceeds a preset threshold value, illumination is automatically applied to activate the proton pump, so that the urea circulation function is enhanced as required. Through closed-loop light control and a subcellular organelle energy channel, on-demand, efficient and high-temporal-spatial-resolution dynamic enhancement of the liver organ urea circulation function is achieved.

The present invention relates to a novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a pharmaceutical composition for potassium-competitive inhibition of gastric acid secretion and a pharmaceutical composition for preventing or treating diseases caused by gastric acid secretion disorder, the pharmaceutical composition containing the novel pyrrole derivative compound or a pharmaceutically acceptable salt thereof as an active component. The pyrrole derivative compound or the like according to the present invention is a potassium-competitive acid blocker (PCAB) and has an excellent H+ / K+ adenosine triphosphatase (ATPase) (proton pump) inhibition effect, and is thus widely used as a therapeutic agent for diseases caused by gastric acid secretion disorder.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

A pharmaceutical formulation according to some embodiments comprises: an immediate-release part for eluting an active ingredient in a pH-independent manner; and an enteric part for eluting the active ingredient in a pH-dependent manner, wherein the active ingredient may comprise a proton pump inhibitor, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Some embodiments of the present invention enable immediate absorption of drugs while maintaining prolonged pharmacological efficacy.

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrate into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, revitalizing cells, modulating T cell function, improving feed efficiency, prolonging lifespan and treating cancer.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

The application discloses a sequential anti-tumor strategy based on improvement of tumor microenvironment (TME) combined with CAR T and application thereof, and belongs to the technical field of biological medicine, which simultaneously improves tumor fibrosis and acid microenvironment by applying tumor-related fibroblast (CAF) targeting drugs and proton pump inhibitors, and sequentially injects CAR T combined therapy for solid tumors, wherein the CAF targeting drugs are selected from tretinoin, calcipotriol, losartan and minnelide, the proton pump inhibitors are selected from lansoprazole, omeprazole, pantoprazole, rabeprazole and esomeprazole, and the CAR T receptor or ligand is selected from mesothelin, protein tyrosine kinase 7, NKG2D, CD47, B7-H3, MUC1 and HER2; the sequential administration strategy first destroys the dense physical barrier of the tumor microenvironment, improves the acidity of the tumor site, ensures the infiltration, survival and proliferation of CAR T at the tumor site, and then targets and inhibits the growth of solid tumors, especially high-malignancy triple-negative breast cancer, by using the specificity of CAR T.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

A proton pump modulator, and a use of the proton pump modulator in preparing a reagent. The reagent is used for improving learning ability, treating cognitive impairment, and / or treating neurodegenerative diseases. Also involved are an ATP6V1B2 modulator and a use thereof in preparing a reagent used for improving learning ability, treating cognitive impairment, and / or treating neurodegenerative diseases.

This invention provides a lyophilized powder injection of a proton pump inhibitor and its use therein, the lyophilized powder injection comprising a compound of formula (I) and an excipient. The powder injection provided by this invention is stable in properties, has controllable quality, and its preparation process is highly reproducible, meeting the needs of commercial production. Formula (I).

The present invention relates to: a novel 4-cyclopropyl pyrrole derivative exhibiting proton pump inhibitory activity and, more specifically, to a 4-cyclopropyl pyrrole derivative exhibiting excellent proton pump inhibitory activity or a pharmaceutically acceptable salt thereof; and a use thereof for preventing or treating gastrointestinal inflammatory diseases or gastric acid-related diseases.

This invention provides a bioimaging device based on photosensitive proteins, comprising a photosensitive imaging unit, an image reading unit, and an image reconstruction unit. The photosensitive imaging unit includes a photosensitive protein membrane and two pixel grid gel layers. The photosensitive protein membrane includes a photosensitive protein with a light-driven proton pump function. The photosensitive imaging unit converts the light intensity information of an external target image into proton concentration information of the gel material within each grid of the pixel grid gel layers. The image reading unit detects the proton concentration change information of the gel material within each grid of the pixel grid gel layers. The image reconstruction unit restores the proton concentration change information of the gel material to the light intensity information at each grid, and converts the light intensity information at the grid into grayscale information to obtain the target image. The bioimaging device provided by this invention has high image resolution.

The invention relates to application of a proton pump regulating agent for regulating ATP6V1B2 and / or a functional active fragment thereof in preparation of a reagent for preventing and / or treating diseases, and the diseases comprise cerebral apoplexy.

Omeprazole is used as a widely applied proton pump inhibitor and is mainly used for treating various diseases caused by hyperacidity, such as gastric ulcer, duodenal ulcer, reflux esophagitis and the like. The invention relates to a novel application of a commercially available medicine omeprazole, namely the omeprazole has remarkable anti-aging activity. The research on model organism caenorhabditis elegans finds that omeprazole can significantly prolong the life of nematodes. Specifically, when the nematodes are cultured in culture media containing 1.6 mg / mL omeprazole and 3.2 mg / mL omeprazole, the service lives of the nematodes are prolonged by 47.80% and 61.51% respectively, and the effect is extremely rare in current drug research.

The invention relates to the technical field of prescription auditing, and discloses an intelligent pharmacy platform based on linkage of a hospital information system and a reasonable medication system, which screens and manages key controlled medicines such as traditional Chinese medicine decoction pieces, proton pump inhibitors, analgesics, enteral and parenteral nutrition preparations and the like through a clinical pharmacist informatization integrated management system. Through an intelligent management platform, precise control and intervention of traditional Chinese medicine decoction pieces and key monitoring drugs such as proton pump inhibitors, analgesics and enteral and parenteral nutrition preparations in medical institutions are realized, and a standardized medication path is established. The method successfully solves the core problems that the traditional Chinese medicine decoction piece auditing rule is single and does not accord with the reality in the prescription auditing process in the prior art, the medicine is emphatically monitored, and the medicine diameter management of proton pump inhibitor enteral and parenteral nutrition, analgesics and enteral and parenteral nutrition preparations is not in place. A comprehensive and practical solution is provided for optimization of a prescription auditing system and formulation of clinical drug paths.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.

The application discloses a 3D printing combination tablet for treating helicobacter pylori infection, which comprises three layers from top to bottom, wherein the first layer is a stomach floating delayed release layer, the second layer is a bismuth agent immediate release layer, and the third layer is an enteric layer; the stomach floating delayed release layer comprises a delayed release shell, an antibiotic inner core and an air chamber, the delayed release shell is wrapped outside the antibiotic inner core and the air chamber, and the air chamber is arranged above the antibiotic inner core; the enteric layer comprises an enteric shell and a proton pump inhibitor tablet core, and the enteric shell is wrapped outside the proton pump inhibitor tablet core; and a drug release channel is arranged at the bottom of the stomach floating delayed release layer. The 3D printing combination tablet can realize the immediate release of the bismuth agent, the delayed release of the antibiotic and the pH-dependent release of the proton pump inhibitor in the quadruple drug formula, and solves the problems of complex taking sequence, poor patient compliance and single drug dosage of the drug formula for treating helicobacter pylori infection on the market.

The embodiment of the invention discloses a helicobacter pylori detection primer group based on a targeted high-throughput sequencing technology, a kit and a detection method and application of the helicobacter pylori detection primer group. The primer group in the embodiment of the invention comprises specific primer pairs aiming at mutation sites of Hp species identification genes, subtype identification genes and various drug resistance related genes and human CYP2C19 genotyping sites. Through an innovative primer design strategy, a tNGS detection system constructed by using the primer group can simultaneously complete Hp infection confirmation, pathogenic subtype distinguishing, drug resistance evaluation of six common antibiotics and host proton pump inhibitor metabolic capability (CYP2C19 genotype) analysis in single detection; and a comprehensive and efficient solution is provided for precise diagnosis and individualized medication of Hp infection.

The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides use of mesdopetam in the manufacture of a medicament for the treatment of gastrointestinal disorders in a subject in need thereof wherein the medicament is to be administered to the subject. The present invention also relates to a method of treating gastrointestinal diseases in a subject in need thereof comprising administering to the subject mesdopetam and pharmaceutical composition.

Described are analogs of aztreonam and disulfiram of Formula I, II, and III. These compounds can be used to treat bacterial infections in a subject. Also disclosed is the use of aztreonam and disulfiram for treating H. pylori infections. Combinations of the disclosed analogs and / or aztreonam and disulfiram with additional antibiotics and proton pump inhibitors are also disclosed.

The present invention relates to a pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

A method of treating and / or preventing gastric ulcers, said method comprising administering by injection a therapeutically effective amount of a composition comprising: c) a first agent selected from the group consisting of: a medium chain triglyceride and a long chain triglyceride; and d) a second agent comprising a proton pump inhibitor or pharmaceutically or veterinary acceptable salt, wherein the composition is adapted for sustained release of a therapeutically effective amount of the proton pump inhibitor to a subject in need thereof.

The invention discloses a pharmaceutical composition for protecting gastric mucosa, a gastric floating buoyant raft system of the pharmaceutical composition and a preparation method of the gastric floating buoyant raft system. The mass ratio of the proton pump inhibitor to the traditional Chinese medicine extract is (1: 2)-(1: 4), and the traditional Chinese medicine extract is prepared from gingerol oil and pogostemon cablin essential oil according to the mass ratio of (0.5-3): 1. The pharmaceutical composition is prepared into a gastric floating raft system, and the dosage form is in a solution state under preparation and in-vitro conditions; after being orally taken and entering the stomach, the gel buoyant raft is rapidly subjected to phase transformation in the environment of low-pH gastric juice and expands to form a layer of light gel buoyant raft which is low in density, compact in structure and certain in mechanical strength. The gel raft can stay on the surface of gastric juice for a long time, so that retention and slow release of the medicine in the stomach are realized, and the local action effect is enhanced. Compared with a single chemical medicine, the compound preparation is mild in medicine property, the irritation is obviously reduced, the curative effect is enhanced through the synergistic effect of multiple components, and the adverse reaction is reduced.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

The embodiment of the invention provides an application of a proton pump inhibitor or a derivative thereof, or a compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof in preparation of anti-xerophthalmia drugs. The proton pump inhibitor is prepared from any one or a combination of at least two of omeprazole, lansoprazole, pantoprazole, rabeprazole, reminoprazole, esomeprazole or tenatoprazole. According to the application, the proton pump inhibitor is loaded on the self-assembled nucleic acid, so that the composite material has efficient corneal cell membrane penetrating capacity, and can remarkably inhibit expression of inflammatory factors and improve the ocular surface inflammation microenvironment; in addition, the compound also has relatively good biological safety, shows an excellent treatment effect on in-vivo and in-vitro xerophthalmia models, and provides a new choice for clinical xerophthalmia treatment.

The invention provides a freeze-dried powder injection of a proton pump inhibitor and application of the freeze-dried powder injection. The freeze-dried powder injection comprises a compound shown in a formula (I) and an excipient. The powder injection provided by the invention is stable in property and controllable in quality, the preparation process is good in repeatability, and commercial production requirements can be met. Formula (I).